Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares
Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares
The purpose of this study is to determine whether mesalamine is effective vs. placebo in the
 prevention of diverticulitis flares in a 24-months follow-up.

 The primary end-point of the study is the incidence of diverticulitis flares. Will be made a
 clinical diagnosis of uncomplicated diverticulitis: fever, leukocytosis, abdominal pain and
 altered intestinal motility.
Inclusion Criteria:

 -  age ≥ 18 years

 -  both males and females patients

 -  positive history of acute diverticulitis flare during the last year. The patients will
 be recruited only after the complete clinical remission of diverticulitis flare.

 -  patients who have given their free and informed consent

 Exclusion Criteria:

 -  complicated diverticulitis(fistulas, stenosis, abscesses and/or bleeding)

 -  ascertained hypersensitivity to the salicylates

 -  any severe pathology that can interfere with the treatment or the clinical or
 instrumental test of the trial

 -  clinically significant renal or hepatic impairment

 -  esophageal, gastric or duodenal ulcer within 30 days prior to randomisation

 -  patients with active malignancy of any type, or history of a malignancy (patients with
 a history of malignancies that have been surgically removed and who have no evidence
 of recurrence for at least five years before study enrollment are also acceptable)

 -  treatment with any investigational drug within the previous 30 days

 -  treatment with lactulose or with any compound that lowering the colonic pH can prevent
 the release of the active moiety from the tablets

 -  recent history or suspicion of alcohol abuse or drug addiction

 -  patients who become unable to conform to protocol

 -  patients with ascertained pregnancy

 -  previous participation in this study